Kyowa Hakko launches immune activation paraprobiotic

5-Oct-2020

The ingredient is supported by ten human trials consisting of eight efficacy studies and two safety studies

Kyowa Hakko launches immune activation paraprobiotic

Kyowa Hakko has launched a novel dietary supplement ingredient called Immuse, a patented strain of Lactococcus lactis strain Plasma characterised as a heat-killed lactic acid bacteria (paraprobiotic) that funtions to activate the immune system.

The strain, discovered by Kyowa Hakko parent company Kirin Holdings acts by activating plasmacytoid dendritic cells (pDC). These cells have been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, providing broad range immune support.

A series of safety data including in vitro, in vivo and in human have been collected on the ingredient.

Suitable for applications including tablets, capsules and gummy formulations, Immuse is currently sold in the form of gummies, tablets, yoghurts and functional beverages in Japan. Those products were registered with the Consumer Affairs Agency of the Japanese government as a “Food with Function Claims.”

“We could not be more thrilled to integrate the immune support benefits of Immuse into the US market,” said Elyse Lovett, Senior Marketing Manager at Kyowa Hakko USA: “A strong immune system is critical for good health, and Immuse is a unique dietary supplement ingredient that offers broad range immune support.”

Sign up for your free email newsletter

Lovett continued: “With more consumers looking for ways to enhance their immune system and stay healthy throughout the year, we are confident that Immuse, backed by both Kirin Holdings and Kyowa Hakko, will open new doors for consumers desiring a novel option for brand range immune support.”

Companies